TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9115058
Drug: Alprazolam 4
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam 4 mg
Study: 9115058
Drug: Alprazolam 8
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam 8 mg
Study: 9115058
Drug: Alprazolam 10
Normalized name: alprazolam 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 10 mg
Study: 2716477
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day) with naloxone (1.6 mg/h for 4 h)
Study: 2716477
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day) with saline
Study: 1017879
Drug: +Pat. (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: +Pat. (antibiotic prophylaxis with penicillins or cephalosporins)
Study: 1017879
Drug: ‐Pat. (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐Pat. (no antibiotic treatment)
Study: 31326458
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily (G/M group)
Study: 31326458
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride 4 mg once daily (G group)
Study: 26975399
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1% (four times daily for 6 weeks post-surgery)
Study: 26975399
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative care with steroid drop
Study: 26088896
Drug: Perampanel (DB-PER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (DB-PER 12 mg)
Study: 23510102
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing counseling with 21‐mg nicotine patch
Study: 23510102
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (one session of brief advice to quit smoking) with 21‐mg nicotine patch
Study: 21864166
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg daily for 1 year)
Study: 19825960
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events after treatment
Study: 11737375
Drug: Saquinavir hard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir hard gel
Study: 9161875
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 0.1 IU/kg/day
Study: 9161875
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 0.2 IU/kg/day
Study: 9161875
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 0.3 IU/kg/day
Study: 8260285
Drug: Remotely controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely controlled mechanical pump for contrast injection
Study: 8260285
Drug: Hand injection
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand injection of contrast
Study: 12942029
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of spironolactone plus standard therapy
Study: 12942029
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only (Control group)
Study: 1342896
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg once daily for 7 days
Study: 1342896
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once daily for 7 days
Study: 3908127
Drug: DDP (cis‐diammine‐dichloroplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group A with heavy osmotic hydration
Study: 3908127
Drug: DDP (cis‐diammine‐dichloroplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group B over 3 consecutive days
Study: 26385228
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (100 mg daily for 8 weeks)
Study: 25297013
Drug: ALD403 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALD403 1000 mg
Study: 18589423
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg daily for 15 days
Study: 7740123
Drug: Electrodermal conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrodermal conditioning with intermixed pre-training and compound training trials; specific dosage and duration not mentioned.
Study: 7740123
Drug: Overshadowing control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overshadowing control group; specific dosage and duration not mentioned.
Study: 6290754
Drug: Etoposide maintenance
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide maintenance therapy
Study: 6290754
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further maintenance therapy
Study: 6290754
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (ACO)
Study: 30897134
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy and pulmonary rehabilitation
Study: 15363007
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (800 micro g budesonide) for 12 weeks
Study: 11822764
Drug: high-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose therapy
Study: 9516059
Drug: Low-dose ramipril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ramipril (1.25 mg) over 4 weeks
Study: 8071053
Drug: Iopromide (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (370 mg I/mL)
Study: 8071053
Drug: Iopamidol (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (370 mg I/mL)
Study: 8071053
Drug: Iohexol (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (350 mg I/mL)
Study: 3127845
Drug: Amitriptyline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline at low plasma drug levels
Study: 3127845
Drug: Amitriptyline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline at medium plasma drug levels
Study: 3127845
Drug: Amitriptyline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline at high plasma drug levels
Study: 3127845
Drug: Amitriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline treatment in patients aged 25 to 65 years
Study: 3127845
Drug: Amitriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline treatment in patients aged 65 to 80 years
Study: 29610026
Drug: Accelerated corneal
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated corneal crosslinking (CXL) using higher fluence (7.2 J/cm2) and treatment time (4 minutes)
Study: 27716157
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (6.7 ml)
Study: 27716157
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (10 ml)
Study: 27716157
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% (20 ml)
Study: 20575271
Drug: Hib vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccine
Study: 15966757
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg/day
Study: 17646493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1.5 microg/kg
Study: 14692723
Drug: Kava special
Normalized name: KAVA
DrugBank: Kava (DB01322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava special extract WS 1490 (150 mg/d, 3 x 1 capsule of 50 mg/d)
Study: 18466078
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperthyroidism
Study: 24200100
Drug: Integrative Treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative Treatment (IT)
Study: 12927999
Drug: Newer cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer cytotoxic agents (gemcitabine, PEG-liposomal doxorubicin, topotecan) in combination with platinum-based therapy
Study: 12927999
Drug: Standard platinum/taxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard platinum/taxane therapy (carboplatin and paclitaxel)
Study: 1622957
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 5% eutectic mixture of lignocaine and prilocaine (EMLA) (n = 15)
Study: 6381775
Drug: Moxalactam and
Normalized name: moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam and ampicillin sodium therapy
Study: 6381775
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate and ampicillin therapy
Study: 26686567
Drug: Lomitapide (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomitapide (10-60 mg)
Study: 24794720
Drug: 0.5-mg nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg nitroglycerin gel (1 mL) applied vaginally 30 min prior to IUD placement
Study: 24794720
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo gel applied vaginally 30 min prior to IUD placement
Study: 20350942
Drug: vicriviroc-ritonavir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: vicriviroc-ritonavir (30 and 100 mg)
Study: 20350942
Drug: vicriviroc-ritonavir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: vicriviroc-ritonavir (150 and 100 mg)
Study: 23155151
Drug: ritonavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritonavir (100 mg)
Study: 20350942
Drug: vicriviroc (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: vicriviroc (200, 250, or 300 mg)
Study: 20350942
Drug: vicriviroc (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: vicriviroc (150, 200, or 250 mg)
Study: 16227990
Drug: Combination immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations
Study: 16227990
Drug: Early T-cell
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early T-cell infusions
Study: 16227990
Drug: Combination vaccine
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccine therapy and adoptive T-cell transfer
Study: 9456253
Drug: Indinavir in
Normalized name: Product containing indinavir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir in combination with nucleoside analogue reverse transcriptase inhibitors
Study: 7610506
Drug: LHRH analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH analogues treatment
Study: 2540581
Drug: Lonidamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonidamine (up to 1050 mg/day)
Study: 2540581
Drug: MVP (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, cisplatin 100 mg/m2)
Study: 779590
Drug: Alprenolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (400 mg daily, increased to 533 mg)
Study: 779590
Drug: Pindolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (20 mg daily, increased to 25 mg)
Study: 21671884
Drug: Tipranavir/ritonavir (TPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir/ritonavir (TPV/r) administered twice daily for 10 days
Study: 21671884
Drug: Darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (DRV/r) administered twice daily for 10 days
Study: 21671884
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) administered alone for 10 days
Study: 2010565
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg single dose)
Study: 6859836
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 or 200 mg daily for 5 days)
Study: 6859836
Drug: Aspirin (3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.25 g daily for 5 days)
Study: 26432693
Drug: Evidence-based depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based depression care management for 2 years, including psychotherapy and medication management
Study: 22708640
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (50-100 mg daily)
Study: 18051491
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of paracetamol as a single intravenous preemptive dose
Study: 7759701
Drug: Metoprolol (Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (Controlled Release, 200 mg once daily)
Study: 7759701
Drug: Nifedipine (Retard,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (Retard, 20 mg twice daily)
Study: 29486881
Drug: Topical regenerative
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regenerative agent
Study: 26921460
Drug: Adjunctive antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antimicrobial photodynamic therapy (aPDT) with indocyanine green (ICG) + SRP
Study: 11369986
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (1000 ml)
Study: 25568553
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride 0.9% (1000 ml)
Study: 22233204
Drug: Tofacitinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (30 mg twice daily for 6 days)
Study: 22233204
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg single dose)
Study: 20434823
Drug: BIG Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIG Bone Injection Gun
Study: 16120067
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg twice daily for 5 days)
Study: 16120067
Drug: Omeprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (30 mg once daily for 6 days)
Study: 12131606
Drug: Infliximab 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 5, 10, or 20 mg/kg
Study: 7779149
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam (2 x 20 mg on days 1 and 2)
Study: 87082
Drug: Oral retinoid
Normalized name: tretinoin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral retinoid (Ro 10‐9359) and UVB radiation (Selective Ultraviolet Phototherapy=SUP)
Study: 87082
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy only (control group)
Study: 23333292
Drug: buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine/naloxone treatment for 12 weeks
Study: 19435390
Drug: Nonpharmacologic methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic methods or other medications
Study: 14722734
Drug: ZD9331 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD9331 in combination with cisplatin (100 mg/m2 and 50 mg/m2)
Study: 14722734
Drug: ZD9331 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD9331 in combination with cisplatin (130 mg/m2 and 50 mg/m2)
Study: 14722734
Drug: ZD9331 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD9331 in combination with cisplatin (130 mg/m2 and 75 mg/m2)
Study: 14722734
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ZD9331 and cisplatin)
Study: 2893877
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation at a total dose over 2000 cGy (group I)
Study: 2893877
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation at a total dose of 1800 cGy (group II)
Study: 23240729
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages (TM) for 12 weeks
Study: 17298190
Drug: Multifactorial educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial educational intervention by a pharmacist including disease information, drug therapy, diet education, and active telephone follow-up.
Study: 9220319
Drug: Prophylactic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic low-dose dopamine (2 mg/kg/min) administered 1 hour before IL-2 and discontinued 6-12 hours after maximum IL-2 doses.
Study: 9220319
Drug: Prophylactic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic low-dose dopamine (2 mg/kg/min).
Study: 7698967
Drug: Saphenous vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous vein patch
Study: 7698967
Drug: PTFE patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE patch
Study: 2439856
Drug: Empirically devised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically devised regimen of forceful spinal manipulation and injections of a dextrose‐glycerine‐phenol ('proliferant') solution
Study: 2439856
Drug: Parallel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel treatment with less extensive initial local anaesthesia and manipulation, and saline substitution for proliferant
Study: 27582635
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group B)
Study: 25268778
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone
Study: 18809731
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg b.i.d.)
Study: 18809731
Drug: Desvenlafaxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (100 mg/day)
Study: 9935203
Drug: MAGE-3.A1 peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-3.A1 peptide (3 subcutaneous injections at monthly intervals)
Study: 2719466
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg every 12 h for 3 days)
Study: 2719466
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg by 30-min intravenous infusion)
Study: 31127607
Drug: Individualized FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized FSH dose (100 IU/d for predicted hyper responders)
Study: 31127607
Drug: Standard FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSH dose (150 IU/d)
Study: 31127607
Drug: Individualized FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized FSH dose (450, 225, or 100 IU/d based on AFC)
Study: 28778281
Drug: High progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High progesterone levels on the day of hCG administration
Study: 28778281
Drug: Normal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normal progesterone levels on the day of hCG administration
Study: 25662406
Drug: KRM-20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM-20 (20 mg)
Study: 25662406
Drug: KRM-20 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM-20 (6 mg)
Study: 25662406
Drug: KRM-20 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM-20 (60 mg)
Study: 25662406
Drug: KRM-20 (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM-20 (16 mg)
Study: 25662406
Drug: KRM-20 (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM-20 (1.6 mg)
Study: 17572615
Drug: Conventional corpectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional corpectomy (CC)
Study: 17572615
Drug: Both CPW
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CPW and CC
Study: 9885179
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acetylsalicylic acid (ASA)
Study: 9885179
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acetylsalicylic acid (ASA) + 2 x 200 mg dipyridamole
Study: 8279943
Drug: PAF antagonist
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAF antagonist Ro 24‐4736, 10 mg orally
Study: 3569338
Drug: 150 mCi
Normalized name: samarium Sm 153 lexidronam 150 mCi/3 mL (5,550 MBq/3 mL) INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mCi 131I (therapeutic dose for all patients)
Study: 29784451
Drug: 60 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm)
Study: 15185427
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (11 microg twice weekly)
Study: 11714065
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, applied once daily for 7 days
Study: 8237866
Drug: Two FeSO4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two FeSO4 tablets (100 mg Fe) daily
Study: 8237866
Drug: One GDS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One GDS capsule (50 mg Fe) daily
Study: 8237866
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplement
Study: 2897260
Drug: GHRH administration
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administration in all groups